Cargando…

Cardiovascular Risk Management and Hepatitis C: Combining Drugs

Direct-acting antivirals (DAAs) are known victims (substrate) and perpetrators (cause) of drug–drug interactions (DDIs). These DAAs are used for the treatment of hepatitis C virus (HCV) infections and are highly effective drugs. Drugs used for cardiovascular risk management are frequently used by HC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smolders, Elise J., ter Horst, Peter J. G., Wolters, Sharon, Burger, David M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451722/ https://www.ncbi.nlm.nih.gov/pubmed/30259390 http://dx.doi.org/10.1007/s40262-018-0710-1

Ejemplares similares

Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update
por: Smolders, Elise J., et al.
Publicado: (2019)

Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment
por: Smolders, Elise J., et al.
Publicado: (2016)

Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment
por: Marra, Fiona, et al.
Publicado: (2020)

Novel drugs in the management of difficult-to-treat hepatitis C genotypes
por: Cartwright, Emily J, et al.
Publicado: (2013)

Cost-effectiveness of hepatitis C virus screening, and subsequent monitoring or treatment among pregnant women in the Netherlands
por: Eijsink, Job F. H., et al.
Publicado: (2020)

Effect of Chronic Hepatitis C Virus Treatment by Combination Therapy on Cardiovascular System
por: Biomy, Reda, et al.
Publicado: (2017)

Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy
por: Drazilova, Sylvia, et al.
Publicado: (2018)

Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate‐Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy
por: Bukkems, Vera E., et al.
Publicado: (2020)

Induction of Combination Therapy for the Management of Hepatitis C: An Observational Study
por: Khan, Sultan Z, et al.
Publicado: (2020)

Translating biomonitoring data into risk management and policy implementation options for a European Network on Human Biomonitoring
por: Smolders, R, et al.
Publicado: (2008)

2253. Comparison of Cardiovascular Risk in Patients Infected With HIV and Hepatitis C
por: Ma, Jimmy, et al.
Publicado: (2018)

Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications
por: Smolders, E. J., et al.
Publicado: (2016)

Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action
por: Tillie, Nicole A., et al.
Publicado: (2016)

The challenge of choosing in cardiovascular risk management
por: Hoogeveen, R. M., et al.
Publicado: (2021)

Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions
por: Langness, Jacob A, et al.
Publicado: (2017)

Evaluating the Cardiovascular Risk in an Aging Population of People With HIV: The Impact of Hepatitis C Virus Coinfection
por: Lang, Raynell, et al.
Publicado: (2022)

Risk of Cardiovascular Disease Due to Chronic Hepatitis C Infection: A Review
por: Babiker, Ahmed, et al.
Publicado: (2017)

Cardiovascular risk assessment by electrocardiographic Holter monitoring in patients with chronic hepatitis C
por: Poliwczak, Adam R., et al.
Publicado: (2020)

Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals
por: Ramadan, Mohammad Said, et al.
Publicado: (2022)

Impact of Specialty Pharmacy on Telaprevir-Containing 3-Drug Hepatitis C Regimen Persistence
por: Henderson, Rochelle R., et al.
Publicado: (2014)

Prevalence and determinants of hepatitis C virus infection among female drug injecting sex workers in Glasgow
por: Taylor, Avril, et al.
Publicado: (2008)

Prevalence and Seroincidence of Hepatitis B and Hepatitis C Infection in High Risk People Who Inject Drugs in China and Thailand
por: Jackson, J. Brooks, et al.
Publicado: (2014)

Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives
por: Devabhaktuni, Madhuri, et al.
Publicado: (2009)

Combining antihypertensive and antihyperlipidemic agents – optimizing cardiovascular risk factor management
por: Zamorano, José, et al.
Publicado: (2011)

Chronic Viral Hepatitis and Metabolic Syndrome/Cardiovascular Risk
por: Jarcuska, Peter, et al.
Publicado: (2018)

Hepatitis C virus and cardiovascular: A review
por: Petta, Salvatore
Publicado: (2017)

Risk Management in Drug-Device Combination Product Development
por: Kumoluyi, Robin, et al.
Publicado: (2022)

Hepatic Diacylglycerol-Associated Protein Kinase Cε Translocation Links Hepatic Steatosis to Hepatic Insulin Resistance in Humans
por: ter Horst, Kasper W., et al.
Publicado: (2017)

Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate
por: Mangoni, Arduino A, et al.
Publicado: (2018)

Factors to Improve the Management of Hepatitis C in Drug Users: An Observational Study in an Addiction Centre
por: Moussalli, Joseph, et al.
Publicado: (2010)

Hepatitis C virus risk among young people who inject drugs
por: Mateu-Gelabert, Pedro, et al.
Publicado: (2022)

Hepatitis C new drugs
por: Wedemeyer, H
Publicado: (2010)

Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection
por: Ke, Ruian, et al.
Publicado: (2015)

Photo-induced drug eruption in a patient on combination simeprevir/sofosbuvir for hepatitis C
por: Eyre, Zachary W., et al.
Publicado: (2016)

Association of Medicaid Managed Care Drug Carve Outs With Hepatitis C Virus Prescription Use
por: Auty, Samantha G., et al.
Publicado: (2021)

Impact of HIV and chronic kidney disease comorbidities on hepatitis C treatment choices, drug–drug interactions and hepatitis C cure
por: Ali, Salamat, et al.
Publicado: (2020)

Consensus about managing gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs?
por: Yeomans, Neville D
Publicado: (2015)

Hepatitis C Treatment & Management
por: Andronescu, D, et al.
Publicado: (2014)

Cardiovascular risk management in patients with active Ankylosing Spondylitis: a detailed evaluation
por: Heslinga, Sjoerd C, et al.
Publicado: (2015)

Cobicistat: A case of mislabelled drug‐drug interaction risk?
por: Burger, David M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9nl6qj4roe8i8ts84jsb6n7qt8